Wolverine Stack

• Wolverine is a marketed two-peptide COMBINATION (blend), not a single compound: BPC-157 + TB-500 (the thymosin β4 fragment), aimed at tissue repair and recovery.
• Its effects and evidence are the individual components' — BPC-157 (repair, angiogenesis, anti-inflammatory) and TB-500 (cell migration, anti-scarring) — combined on a mechanistic rationale, NOT on trials of the actual stack.
• ⚠️ The headline '87.5% knee-pain relief' is weak: it comes from a 16-patient retrospective review whose combination arm was only 4 people. Don't read it as robust evidence.
• Both peptides are pro-angiogenic, so the cancer/active-malignancy contraindication is the key safety point. Neither is FDA-approved, and both are WADA-banned.

The Wolverine Stack pairs the two most popular regenerative research peptides — BPC-157 and TB-500 — in one 'healing stack', named for the comic character's regeneration. Like GLOW and KLOW, it is a convenience combination: there is no 'Wolverine molecule', just two known peptides used together.

The honest framing for any blend applies: the benefits are whatever the components do, the evidence is the components' evidence, and the main practical issues are dosing and the shared safety profile. Everything below is research context, not medical guidance.

The rationale is complementary actin-pathway healing: BPC-157 increases actin production and drives angiogenesis/vascular repair while damping inflammation, and TB-500 sequesters actin to mobilize cells (fibroblasts, immune cells) to the injury and limit scar formation. Together they're claimed to accelerate tissue repair. Important caveat: this is a mechanistic rationale, not combination-trial evidence — there is no published trial of the BPC-157/TB-500 stack itself.

There is no approved dosing. The schedule is asymmetric because the two peptides have very different durations — that's the one genuinely useful practical point about this blend.

• General recovery: BPC-157 ~250 mcg twice daily + TB-500 ~2 mg twice weekly
• Intensive injury: BPC-157 ~500 mcg twice daily + TB-500 ~2.5 mg twice weekly
• BPC-157's short half-life drives the daily dosing; TB-500's longer action allows twice-weekly
• Calculate each peptide against its own range; many users simply dose the two separately

If using two separate vials rather than a pre-made blend, do NOT mix them in one syringe — reconstitute and dose each peptide separately, and use separate injection sites if dosing the same day.

• Reconstitute each peptide SEPARATELY in its own vial with bacteriostatic water down the vial wall (e.g. 2 mL into a 5 mg vial = 250 mcg per 0.1 mL); swirl gently, never shake.
• Do not combine the two in a single syringe unless they came as a pre-made blend.
• Refrigerate reconstituted solution at 2–8°C and use within ~3–4 weeks; request a COA (HPLC >98% + mass spec) for BOTH peptides.

The profile is the sum of the components: generally mild, with injection-site reactions the most common. The single most important safety point is the cancer contraindication — both BPC-157 and TB-500 are pro-angiogenic, so the stack is contraindicated with any history of cancer or suspicious growths, and users are advised to monitor for unusual tissue growth and avoid combining with chemotherapy or during active malignancy. Human safety data is limited (mostly preclinical), and both peptides are WADA-banned. Avoid in pregnancy/breastfeeding.

There is no trial of the BPC-157/TB-500 combination itself — the evidence base is the individual components (see the BPC-157 and TB-500 monographs), most of it preclinical. The one human dataset often cited for the stack is a 16-patient retrospective intra-articular knee-pain review (Lee & Padgett, 2021) reporting ~87.5% overall relief — but the actual combination arm in that review was just 4 patients, so it is weak evidence and should not be presented as robust support for the stack.

Neither component is FDA-approved, and the blend is sold for laboratory research only, not intended for human consumption. Both BPC-157 and TB-500 are on the WADA Prohibited List — relevant for tested athletes.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.